8-K: Champions Oncology Appoints Robert Brainin as New CEO, Dr. Ronnie Morris Transitions to Executive Chair

Champions Oncology, Inc. announced the appointment of Robert Brainin as its new Chief Executive Officer, effective August 25, 2025, with current CEO Dr. Ronnie Morris transitioning to Executive Chairman.

Summary

• Robert Brainin has been appointed as the new Chief Executive Officer of Champions Oncology, Inc., effective August 25, 2025.
• Dr. Ronnie Morris, the current CEO since 2017, will transition to the role of Executive Chairman of the Board, effective August 25, 2025, and will remain actively involved in strategic initiatives.
• Joel Ackerman, the current Chairman of the Board, will transition to a Board Director role.
• Mr. Brainin, age 54, has served on the Company's Board of Directors since February 2021 and will continue as a Director.
• He brings over 25 years of experience in life sciences and technology, including recent roles as Chief Business Officer at Veracyte and CEO of Genuity Science.
• Mr. Brainin's compensation package includes an annual base salary of $500,000 and eligibility for a discretionary target incentive bonus of 75% of his base salary.
• He will receive equity awards, including 225,000 time-based options vesting over four years and 475,000 performance-based options.
• Performance-based options are tied to specific financial and stock price targets: 62,500 options for $25 million EBITDA, 62,500 options for $15 million data revenue, 150,000 options for $35 million EBITDA or $30 million data revenue (all over consecutive four-quarter periods), and 100,000 options each for average stock closing prices of $16.00 and $24.00 over 45 calendar days.

Sentiment

Score: 8

Explanation: The announcement reflects a positive strategic leadership transition, bringing in a highly experienced CEO with a background aligned with the company's growth ambitions in data and AI, while maintaining continuity with the former CEO in a strategic oversight role. This signals a well-planned move to enhance future growth and value creation.

Positives

• Appointment of Robert Brainin, a highly experienced leader with over 25 years in life sciences and technology, including executive roles at oncology diagnostics and genomics companies, is expected to drive strategic growth.
• The strategic transition of Dr. Ronnie Morris to Executive Chairman ensures continuity of leadership and continued involvement in the company's strategic initiatives.
• The new CEO's expertise aligns with the company's stated goal of expanding beyond core CRO services into a robust data offering and advancing its discovery therapeutics subsidiary, Corellia AI.
• The compensation structure for the new CEO, including significant performance-based equity awards, aligns his incentives directly with key financial and stock price achievements, benefiting shareholders.

Risks

• The employment relationship is at-will, meaning either the Company or the Executive may terminate employment at any time, with or without cause.
• Achievement of the performance-based equity targets (EBITDA, data revenue, and stock price thresholds) is not guaranteed and depends on future company performance and market conditions.
• The Executive's ability to serve on other for-profit boards is subject to Company approval and must not materially interfere with his duties or create conflicts of interest.
• Potential for disputes or legal action related to the non-competition, non-solicitation, or confidentiality clauses if the Executive is deemed to be in breach.

Future Outlook

The company plans to expand beyond its core CRO services into a robust data offering and advance the pipeline of its discovery therapeutics subsidiary, Corellia AI, under the new leadership. The new CEO's experience is expected to guide Champions through its next chapter of growth.

Management Comments

• Joel Ackerman: "I want to thank Ronnie for his outstanding leadership and vision since 2017, and I am thrilled he will continue to play an integral role as Executive Chair. As we expand beyond our core CRO services into a robust data offering, Robs expertise and track record of driving growth in innovative life sciences businesses make him the ideal leader to guide Champions through its next chapter."
• Robert Brainin: "I am honored and excited to join Champions at such a pivotal time. The strength of Champions core CRO services provides a tremendous foundation to expand our emerging data platform and advance the pipeline of our discovery therapeutics subsidiary, Corellia AI. I look forward to working alongside this talented team to build on the companys momentum and create value for our customers, employees, and shareholders."
• Dr. Ronnie Morris: "I am incredibly proud of what we have accomplished together and the outstanding team we have assembled. I have complete confidence that Rob is the right leader to take Champions into its next phase of growth, and I look forward to supporting him and the team in realizing the companys full potential."

Industry Context

Champions Oncology operates in the specialized field of oncology contract research services. The appointment of a new CEO with a strong background in oncology diagnostics, genomics, and data-driven businesses, coupled with the strategic shift towards a 'robust data offering' and 'discovery therapeutics subsidiary (Corellia AI)', aligns with broader industry trends. The life sciences sector is increasingly leveraging big data, artificial intelligence, and advanced analytics to accelerate drug discovery, development, and personalized medicine, positioning Champions Oncology to capitalize on these evolving opportunities.

Management Changes

Corporate Governance

Related Party Transactions

• There are no transactions between the Company and Mr. Brainin that are subject to disclosure under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: The appointment of an experienced CEO and the strategic transition of the former CEO are likely to be viewed positively, potentially enhancing confidence in the company's future growth prospects and strategic direction. The performance-based compensation for the new CEO aligns his interests with shareholder value creation.
• Employees: A new CEO may bring changes in operational focus and strategic priorities, potentially impacting organizational structure and roles.
• Customers: The new CEO's background in oncology diagnostics and genomics, coupled with the company's focus on expanding data offerings, could lead to enhanced and more innovative services for biopharma clients.
• Management: The leadership transition provides a clear succession plan and defines new roles for key executives, ensuring continuity and strategic focus.

Next Steps

• Robert Brainin will officially commence his role as Chief Executive Officer on August 25, 2025.
• Dr. Ronnie Morris will transition to Executive Chairman of the Board on August 25, 2025.
• Joel Ackerman will transition to a Board Director role on August 25, 2025.
• The Board of Directors will set goals and objectives for the CEO's annual bonus within 30 days after the beginning of the fiscal year (FY2026).
• The company plans to continue its expansion beyond core CRO services into a robust data offering.
• The company aims to advance the pipeline of its discovery therapeutics subsidiary, Corellia AI.

Key Dates

Recommendation

Keywords

Champions Oncology, CSBR, CEO appointment, Robert Brainin, Ronnie Morris, Executive Chairman, corporate governance, life sciences, oncology, CRO services, data platform, Corellia AI, executive compensation, stock options, SEC filing, 8-K